← 返回

理解 NK 细胞生物学以驾驭 NK 细胞疗法:靶向肿瘤及更广领域

英文原题:Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond.

查看英文原题

Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond.

PubMed 2023/07/18(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

基因工程免疫细胞疗法已部分改变癌症治疗格局,例如CAR-T 细胞已用于治疗部分血液系统恶性肿瘤。但若要将治疗拓展到更多癌症类型,仍需解决多项局限。自然杀伤(NK)细胞是先天免疫细胞,在肿瘤免疫监视中具有独特生物学特征。尤其是健康供者来源NK细胞可作为基因工程免疫细胞疗法的来源。因此,NK细胞、CAR-NK细胞以及可诱导NK细胞抗体依赖性细胞毒作用的抗体等NK疗法逐渐兴起。随着基因工程和细胞生物学技术进步,NK细胞疗法已成为治疗多种癌症、病毒感染和衰老相关疾病的有前景方法。本综述简要介绍NK细胞特征,总结可能从NK疗法中获益的疾病,并讨论近期过继性NK细胞输注及调节NK细胞活性药物的临床前和临床研究。

展开英文摘要原文

Gene-engineered immune cell therapies have partially transformed cancer treatment, as exemplified by the use of chimeric antigen receptor (CAR)-T cells in certain hematologic malignancies.

However, there are several limitations that need to be addressed to target more cancer types. Natural killer (NK) cells are a type of innate immune cells that represent a unique biology in cancer immune surveillance. In particular, NK cells obtained from heathy donors can serve as a source for genetically engineered immune cell therapies.

Therefore, NK-based therapies, including NK cells, CAR-NK cells, and antibodies that induce antibody-dependent cellular cytotoxicity of NK cells, have emerged. With recent advances in genetic engineering and cell biology techniques, NK cell-based therapies have become promising approaches for a wide range of cancers, viral infections, and senescence. This review provides a brief overview of NK cell characteristics and summarizes diseases that could benefit from NK-based therapies.

In addition, we discuss recent preclinical and clinical investigations on the use of adoptive NK cell transfer and agents that can modulate NK cell activity.

论文信息

作者
Shin E、Bak SH、Park T、Kim JW、Yoon SR、Jung H、Noh JY
单位
Aging Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.South Korea
文献类型
综述 · 非美国政府资助研究
期刊
Frontiers in immunology2023
原文标识
PubMed 37539051 · DOI 10.3389/fimmu.2023.1192907